


I am ready for what's next

All patients with mNSCLC will acquire resistance after being treated with an EGFR-TKI¹⁵

Rates of T790M mutations 30 days after progression in RELAY¹²



In RELAY, all patients who progressed were eligible to be tested for T790M mutations,* regardless of exon mutation status.¹⁴

Total EGFR T790M mutation rates at progression were similar between treatment groups (43% CYRAMZA + erlotinib vs 47% placebo + erlotinib).^{12†}

CYRAMZA + erlotinib is a 1L EGFR-TKI option that significantly improves median PFS and supports the subsequent use of targeted therapies at progression^{6,12,15}

*Confirmed with blood plasma samples through biopsy.¹²

† Analysis population consisted of patients with EGFR-activating mutation detected in the post-progression 30-day follow-up sample.¹²
1L=first-line.